查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995507

失眠藥物治療市場：依藥物類別、劑型、通路和最終用戶分類－2026-2032年全球市場預測

Insomnia Pharmacological Treatment Market by Drug Class, Dosage Form, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，失眠藥物治療市場價值將達到 75.2 億美元，到 2026 年將成長到 80.7 億美元，到 2032 年將達到 123.7 億美元，複合年成長率為 7.36%。

主要市場統計數據
基準年 2025 75.2億美元
預計年份：2026年 80.7億美元
預測年份 2032 123.7億美元
複合年成長率 (%) 7.36%

針對失眠症的藥物治療策略制定了一個全面的框架，平衡了臨床療效、安全性權衡、患者異質性和不斷變化的治療重點。

失眠症仍然是神經病學、精神病學、基層醫療和公共衛生領域交叉的複雜臨床挑戰。藥物治療仍是許多患者的核心治療手段，尤其是在單純行為療法效果不佳的情況下。因此，臨床醫生在選擇藥物時會綜合考慮療效、安全性、依賴性風險和日間功能狀態，而保險公司和管理人員則會考慮藥物是否納入醫保範圍以及患者的長期依從性。最終，整體情況涵蓋多種藥物類別，旨在解決不同的病理學標靶並滿足患者的個人需求。

分子層面的創新、監管框架中對臨床實踐的日益重視以及數位技術驅動的護理模式的採用，正在推動失眠藥物治療的重大變革。

由於科學進步、監管環境的演變以及醫療服務模式的改變，失眠症的治療現狀正在經歷一場變革。首先，分子層次的創新正將重點放在γ-氨基丁酸（GABA）調節以外的作用機制上，直接作用於覺醒迴路的Orexin受體拮抗劑正成為值得關注的替代方案。同時，褪黑素受體促效劑的改進和藥物工程技術的進步正推動著人們透過緩釋技術來改善入睡困難和睡眠維持困難。

2025 年貿易政策的最新變化對失眠藥物整個供應鏈的供應鏈策略、購買趨勢和價格壓力產生了哪些影響？

2025年關稅和貿易調整的實施標誌著失眠藥物生產和分銷供應鏈的關鍵轉折點。依賴海外供應商提供活性成分和輔料的製造商立即面臨成本壓力，加速了對供應商基礎和合約條款的審查。為此，許多企業加快了供應商多元化進程，提高了安全庫存水平，並尋求近岸生產方案，以降低跨境關稅波動帶來的風險。

基於詳細細分的洞察揭示了不同治療領域之間的細微差異、劑型的影響、分銷管道的作用以及最終用戶在護理路徑中的需求。

精準的市場區隔對於制定滿足臨床醫生期望和患者需求的產品策略至關重要。藥物類別細分突顯了治療重點的差異。傳統的苯二氮平類藥物，如艾司唑侖、替馬西泮和三唑侖，仍服務於需要快速起效和強效催眠作用的患者，但其依賴性和認知副作用需要謹慎管理。褪黑素受體促效劑，如Agomelatine、褪黑素和雷美替胺，因其能夠調節晝夜節律且耐受性良好，尤其適用於晝夜節律紊亂患者，而備受臨床醫生青睞。非苯二氮平類催眠藥，如依佐匹克隆、Zaleplon和Zolpidem，因其在入睡和維持睡眠方面的有效性而仍然十分重要，其中Zolpidem有緩釋和速釋兩種劑型，可實現個體化的給藥策略。像倫博雷生和蘇沃雷生這樣的Orexin受體拮抗劑，其作用機制已轉變為抑制覺醒，這反映在專家的處方趨勢中。尤其值得注意的是，當合併情緒或焦慮障礙使睡眠管理複雜化時，像多塞平和曲唑酮這樣的抗憂鬱症仍然是可行的治療選擇。

區域比較分析突顯了主要全球市場的採用模式、細微的監管差異、製造地和分銷趨勢。

區域趨勢對失眠藥物的研發、核准、分銷和應用有顯著影響。在美洲，處方醫生的偏好和支付方的結構往往傾向於快速獲得創新藥物，而成本控制措施和處方藥目錄談判則影響長期用藥模式。在北美臨床實務中，具有全新作用機制、強調日間功能的新藥應用顯著增加，遠端醫療的引進也擴大了專科醫師服務社群的範圍。

一份策略性企業行動指南，概述了投資組合多元化、供應鏈韌性、生命週期管理和數位化夥伴關係，以加強失眠治療的交付。

失眠藥物治療領域的主要企業正採用多元化策略來保持競爭力並創造臨床價值。產品系列多元化是重中之重，這些企業在保留傳統藥物的同時，也致力於研發新一代作用機制和改良製劑。許可和策略合作正在加速新型化合物的獲取，並以外部創新補充內部研發能力。

為製藥公司、保險公司和醫療保健提供者提供切實可行的優先建議，以最佳化失眠治療中的產品價值、供應彈性和以患者為中心的治療效果。

產業領導企業應優先考慮能夠平衡臨床差異化與永續商業模式的具體措施。首先，應投資於能夠展現功能性結果（例如日間表現和認知安全性）以及夜間指標的臨床項目。這些數據將增強產品對支付者和處方醫生的價值提案。同時，應加速製劑創新，拓展緩釋製劑和軟膠囊的選擇範圍，以提高老年人和多重用藥患者的用藥依從性。

結合臨床醫生訪談、患者見解、監管審查和數據檢驗的穩健混合研究途徑，得出了失眠治療市場的檢驗前景。

本分析採用嚴謹的混合方法調查方法，確保研究的可靠性和有效性。主要研究包括對睡眠醫學專家、精神科醫生、藥劑師、醫院處方集決策者和行業高管進行結構化訪談和定性討論，以了解臨床實踐模式、採購行為和戰略重點。患者和看護者的回饋也被納入考量，用於評估藥物依從性和耐受性，因為這些因素會影響臨床實踐中的療效。

透過將臨床創新、營運韌性和市場需求整合到簡潔的結論中，我們指導失眠藥物治療的策略行動。

失眠藥物治療正處於一個轉折點，機制特異性創新、不斷發展的分銷管道和供應鏈韌性的交匯融合，正在塑造未來的治療模式。臨床醫師越來越傾向選擇不僅能改善夜間睡眠指標，還能維持日間功能和認知功能的療法。因此，Orexin受體拮抗劑、改良的褪黑素促效劑以及差異化製劑的臨床和商業性價值日益凸顯。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：失眠藥物治療市場：依藥物類別分類

  • 苯二氮平類藥物
    • 艾司唑侖
    • 替馬西泮
    • 三唑侖
  • 褪黑素受體促效劑
    • Agomelatine
    • 褪黑素
    • 拉丁美洲爾修斯
  • 非苯二氮平類催眠藥
    • 依佐匹克隆
    • Zaleplon
    • Zolpidem
      • 緩釋
      • 立即生效
  • Orexin受體拮抗劑
    • 倫博萊桑
    • 斯沃雷桑特
  • 鎮靜性抗憂鬱症
    • 多塞平
    • 特拉佐登

第9章：失眠治療藥物市場（依劑型分類）

  • 膠囊
    • 硬明膠
    • 軟明膠
  • 口服懸浮液
  • 藥片
    • 緩釋
    • 立即發布

第10章：失眠藥物治療市場：依通路分類

  • 醫院藥房
    • 私人的
    • 一般的
  • 網路藥房
    • 市場
    • 專業網路藥房
  • 零售藥房
    • 鏈
    • 獨立的

第11章：失眠藥物治療市場：以最終用戶分類

  • 居家照護環境
    • 輔助住宅
    • 私人居家照護
  • 醫院
    • 綜合醫院
    • 精神病院
  • 專科診所
    • 門診部
    • 睡眠障礙診所

第12章：失眠藥物治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：失眠藥物治療市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：失眠藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國失眠藥物治療市場

第16章：中國失眠藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aa Pharma Inc.
  • Amneal Pharmaceuticals LLC
  • BlaQmax by Akay Natural Ingredients Private Limited
  • Dr. Reddy's Laboratories
  • Eisai Co., Ltd.
  • Fresenius Kabi AG
  • Gemini Pharmaceuticals
  • Idorsia Pharmaceuticals Ltd.
  • Ingenus Pharmaceuticals
  • Makers Nutrition, LLC
  • Merck & Co., Inc.
  • Micro Labs Limited
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi SA
  • Sivem Pharmaceuticals ULC
  • Sleepme Inc.
  • SMP Nutra
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceuticals Company Ltd.
  • TriVue Pharmaceuticals, Inc.
  • Tru Body Wellness
  • Vanda Pharmaceuticals
  • Vera Herbals LLC
  • Viatris Inc.
Product Code: MRR-FB6C9E792FEB

The Insomnia Pharmacological Treatment Market was valued at USD 7.52 billion in 2025 and is projected to grow to USD 8.07 billion in 2026, with a CAGR of 7.36%, reaching USD 12.37 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.52 billion
Estimated Year [2026] USD 8.07 billion
Forecast Year [2032] USD 12.37 billion
CAGR (%) 7.36%

A comprehensive framing of pharmacological strategies for insomnia that balances clinical efficacy, safety trade-offs, patient heterogeneity, and evolving therapeutic priorities

Insomnia persists as a complex clinical challenge that intersects neurology, psychiatry, primary care, and public health. Pharmacological treatment remains a central pillar for many patients, particularly where behavioral interventions alone fail to deliver sufficient relief. Clinicians therefore balance efficacy, safety, dependency risk, and daytime functioning when selecting therapeutics, while payers and administrators factor in formulary placement and long-term adherence. As a result, the therapeutic landscape comprises multiple drug classes that address diverse pathophysiological targets and patient preferences.

Recent years have seen a migration from older sedative-hypnotics toward agents that offer improved tolerability profiles and targeted mechanisms. This shift reflects growing regulatory scrutiny over long-term use of certain benzodiazepines and a parallel rise in interest in orexin receptor antagonists and melatonin receptor agonists. Meanwhile, sedating antidepressants remain widely used off-label due to their dual therapeutic effects for comorbid mood disorders and insomnia, which underscores the importance of integrated care pathways.

Clinical practice increasingly emphasizes personalized regimens aligned with sleep architecture, comorbidities, and patient lifestyle. Consequently, pharmaceutical manufacturers and health systems now focus on differentiated formulations, adherence-supporting packaging, and real-world outcomes research. In short, pharmacological management of insomnia is entering a phase in which therapeutic selection is as much about aligning safety and daily functioning as it is about improving nocturnal sleep measures.

Key transformative changes reshaping insomnia pharmacotherapy that combine molecular innovation, regulatory real-world emphasis, and digitally enabled care models

The landscape of insomnia treatment is undergoing transformative shifts driven by scientific advances, regulatory evolution, and changing care delivery models. First, molecular innovation has prioritized mechanisms beyond gamma-aminobutyric acid modulation, with orexin receptor antagonists emerging as a notable alternative that addresses wakefulness circuitry directly. Concurrently, refinements in melatonin receptor agonists and formulation engineering have sought to reconcile onset and maintenance insomnia through modified-release technologies.

At the same time, commercial dynamics have compelled manufacturers to rethink lifecycle strategies. Patent expirations and generic entry have heightened competition, stimulating investment in value-added formulations, combination approaches, and label expansions that target specific patient cohorts. Parallel to pharmacologic innovation, digital therapeutics and remote monitoring tools have become routine adjuncts, enabling clinicians to track sleep patterns and adjust pharmacotherapy more responsively.

Regulatory frameworks have also shifted, with agencies emphasizing post-marketing safety surveillance and real-world evidence to inform labeling and risk mitigation. This regulatory focus has accelerated the adoption of observational data streams and pragmatic clinical trials to capture long-term outcomes. Taken together, these shifts have created a more nuanced, evidence-driven environment where product differentiation hinges on demonstrable improvements in patient functioning, tolerability, and adherence rather than sleep metrics alone.

How recent trade policy shifts in 2025 have reshaped supply chain strategies, procurement dynamics, and pricing pressures across insomnia pharmacological supply networks

The imposition of tariffs and trade adjustments in 2025 created a material inflection point for supply chains that support insomnia pharmacological manufacturing and distribution. Manufacturers that rely on internationally sourced active pharmaceutical ingredients and excipients experienced immediate cost pressures, catalyzing re-evaluations of supplier footprints and contractual terms. In response, many organizations accelerated supplier diversification, increased safety stock levels, and pursued near-shore manufacturing options to reduce exposure to cross-border tariff volatility.

These changes had downstream effects on procurement strategies within hospitals, pharmacies, and specialty clinics, prompting tighter inventory management and renewed emphasis on supplier qualification. Payers and contracting entities engaged in more intensive negotiations to offset potential price impacts, while pharmacy benefit managers revisited formulary placements to preserve affordability for patients. In parallel, distributors recalibrated logistics planning to mitigate transit delays and compliance costs associated with new tariff classifications.

Strategically, the tariffs prompted renewed investment in supply chain resilience and cost-to-serve modeling. Companies prioritized long-term agreements with geographically diversified suppliers and invested in process improvements to offset margin compression. Consequently, stakeholders adopted a more holistic view of manufacturing economics that integrates regulatory compliance, trade policy risk, and the operational realities of getting medications to patients reliably.

In-depth segmentation-driven insights revealing therapeutic class nuances, dosage form implications, distribution channel roles, and end user care pathway requirements

A nuanced understanding of market segments is essential to design product strategies that meet clinician expectations and patient needs. Drug class segmentation underscores divergent therapeutic priorities: classic benzodiazepines such as estazolam, temazepam, and triazolam continue to serve patients who need rapid onset and strong hypnotic effects, yet they prompt careful stewardship due to dependency and cognitive side effect profiles. Melatonin receptor agonists, including agomelatine, melatonin, and ramelteon, appeal to clinicians seeking circadian alignment and favorable tolerability, especially for patients with circadian rhythm disturbances. Non-benzodiazepine hypnotics like eszopiclone, zaleplon, and zolpidem remain important for their efficacy in sleep initiation and maintenance, with zolpidem available in both extended-release and immediate-release formats to tailor dosing strategies. Orexin receptor antagonists such as lemborexant and suvorexant represent a mechanistic shift toward wakefulness inhibition, which has resonated in specialist prescribing patterns. Sedating antidepressants, notably doxepin and trazodone, persist in therapeutic arsenals when comorbid mood or anxiety disorders complicate sleep management.

Dosage form segmentation shapes both adherence and clinical utility. Capsules, whether hard gelatin or soft gelatin, offer convenient dosing and are often chosen for bioavailability considerations, whereas oral suspensions provide dosing flexibility for pediatric or geriatric cohorts. Tablets, in controlled-release or immediate-release formats, enable clinicians to target specific sleep phases and balance onset with duration. The interplay between form and pharmacokinetics remains a decisive factor in regimen selection.

Distribution channel segmentation determines how products reach patients and which value propositions matter most. Hospital pharmacies in private and public settings prioritize formulary stability and inpatient safety, while online pharmacies, whether large marketplaces or specialty online providers, emphasize convenience, continuity of care, and prescription fulfillment efficiencies. Retail pharmacies, split between chain and independent operators, balance accessibility with personalized counseling, influencing adherence and brand loyalty.

End user segmentation captures divergent care pathways and service requirements. Homecare settings, including assisted living and private homecare, demand simplified regimens, clear caregiver instructions, and packaging that reduces dosing errors. Hospitals, both general and psychiatric, require medications that integrate with acute care protocols and minimize drug-drug interactions. Specialty clinics, such as outpatient centers and dedicated sleep disorder clinics, focus on precision therapies and monitoring to optimize nocturnal architecture and daytime functioning. Understanding these interdependent segments enables targeted product design, channel strategies, and clinical evidence programs that align therapeutic attributes with real-world use cases.

Comparative regional analysis highlighting adoption patterns, regulatory nuances, manufacturing footprints, and distribution dynamics across major global markets

Regional dynamics materially influence how insomnia therapies are developed, approved, distributed, and adopted. In the Americas, prescriber preferences and payer mechanisms often favor rapid access to innovative agents, while cost containment measures and formulary negotiations shape long-term utilization patterns. North American clinical practice has shown notable uptake of newer mechanisms that emphasize daytime functioning, and integration of telehealth has increased specialist reach into community settings.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse healthcare funding models create a mosaic of adoption rates. In several European markets, rigorous comparative effectiveness assessments and health technology appraisals inform reimbursement decisions, prompting manufacturers to align evidence generation with local value frameworks. Meanwhile, certain Middle Eastern and African markets exhibit accelerated private sector uptake where private hospitals and specialty clinics can drive early utilization of differentiated therapies.

The Asia-Pacific region serves both as a manufacturing hub and a dynamic market with varied clinical practices across countries. High-volume generic production coexists with strong demand for novel mechanisms in urban centers where sleep medicine specialties concentrate. Rapid digital health adoption in parts of Asia-Pacific has facilitated hybrid care models that combine pharmacotherapy with remote monitoring and behavioral interventions. Each regional context therefore requires a tailored regulatory engagement plan, supply chain mapping, and commercial strategy that accounts for local clinician preferences, payer structures, and distribution channel strengths.

Strategic corporate playbook outlining portfolio diversification, supply chain resilience, lifecycle management, and digital partnerships to strengthen insomnia treatment offerings

Leading companies in the insomnia pharmacotherapy space are adopting multi-pronged strategies to sustain competitiveness and deliver clinical value. Product portfolio diversification ranks highly, with firms maintaining legacy agents while investing in next-generation mechanisms and formulation enhancements. Licensing arrangements and strategic collaborations accelerate access to novel compounds and complement internal R&D capabilities with external innovation.

Operationally, manufacturers emphasize resilient supply chains and quality-by-design principles to mitigate trade and manufacturing risks. Strategic alliances with contract manufacturing organizations and API suppliers help secure capacity while enabling agile scale-up. Commercially, companies pursue lifecycle management strategies-such as extended-release formulations, fixed-dose combinations, and indication expansions-to differentiate offerings as generics enter the market.

Moreover, a growing number of firms are integrating digital health partnerships to augment pharmacotherapy with adherence tools, sleep trackers, and clinician dashboards. These combinations not only support patient engagement but also generate real-world evidence to underscore product value in payer discussions. Mergers and acquisitions continue to be a tactical route for acquiring pipeline assets, distribution footprints, and therapeutic expertise that accelerate market access and broaden commercial reach.

Practical and prioritized recommendations for manufacturers, payers, and providers to optimize product value, supply resilience, and patient-centered outcomes in insomnia care

Industry leaders should prioritize concrete actions that align clinical differentiation with sustainable commercial models. First, invest in clinical programs that demonstrate functional outcomes such as daytime performance and cognitive safety in addition to nocturnal measures; these data will strengthen value propositions with payers and prescribers. Simultaneously, accelerate formulation innovation by expanding controlled-release and soft gelatin capsule options to improve adherence across geriatric and polypharmacy populations.

On the supply side, implement multi-sourcing strategies for key APIs and establish contingency manufacturing agreements to buffer trade-related disruptions. Engage proactively with procurement and payer stakeholders to design risk-sharing and managed-entry agreements that preserve access while addressing cost pressures. In parallel, forge partnerships with digital therapeutics providers to bundle pharmacologic and behavioral interventions, thereby enhancing long-term outcomes and supporting real-world evidence generation.

Commercially, tailor channel strategies to local market dynamics: strengthen relationships with hospital formulary committees in institutional settings, optimize e-commerce fulfillment for online pharmacy channels, and support independent retail partners with targeted education and adherence programs. Finally, maintain an iterative regulatory engagement plan that leverages post-marketing data and pragmatic studies to adapt labeling and support market access across diverse geographies.

Robust mixed-methods research approach combining clinician interviews, patient insights, regulatory review, and data triangulation to produce validated insomnia drug market perspectives

The research methodology underpinning this analysis combined a rigorous mixed-methods approach to ensure credibility and relevance. Primary research included structured interviews and qualitative discussions with sleep medicine specialists, psychiatrists, pharmacists, hospital formulary decision-makers, and industry executives to capture clinical practice patterns, procurement behaviors, and strategic priorities. Patient and caregiver feedback informed adherence and tolerability considerations that influence real-world effectiveness.

Secondary research leveraged peer-reviewed literature, regulatory guidance documents, clinical trial registries, and pharmaceutical quality standards to validate mechanistic claims and safety profiles. Competitive intelligence processes synthesized public filings, patent literature, and product labeling to map portfolio strategies and lifecycle events. Data triangulation techniques reconciled divergent inputs and emphasized convergence across independent sources.

Analytical methods incorporated thematic coding for qualitative inputs and comparative frameworks to assess product and channel attributes. Limitations included variable availability of longitudinal real-world data across regions and heterogeneity in prescribing guidelines. To mitigate bias, the research applied cross-validation with multiple expert respondents and documented source provenance for reproducibility. Ethical considerations and data protection standards guided all primary interactions, and anonymized reporting protected respondent confidentiality.

Concise conclusion synthesizing clinical innovation, operational resilience, and market imperatives to guide strategic action in insomnia pharmacological care

The pharmacological management of insomnia stands at an inflection point where mechanism-specific innovation, distribution evolution, and supply chain resilience converge to shape future care paradigms. Clinicians increasingly favor therapeutics that not only improve nocturnal sleep metrics but also preserve daytime functioning and cognitive safety. Consequently, orexin receptor antagonists, refined melatonin agonists, and differentiated formulations have assumed greater clinical and commercial importance.

At the same time, trade policy shifts and competitive generic pressures compel organizations to adopt holistic strategies that integrate robust evidence generation, agile supply chain design, and targeted commercialization tactics. Regional heterogeneity and diverse distribution channels necessitate localized engagement plans that respect regulatory expectations and payer dynamics. Ultimately, stakeholders that align rigorous clinical programs with pragmatic operational measures will be best positioned to deliver sustainable value to patients and healthcare systems.

Moving from insight to impact requires deliberate execution: prioritize high-quality outcomes data, invest in patient-centric formulation and support services, and fortify supply chains against policy and market volatility. Doing so will enable healthcare stakeholders to meet the complex needs of patients living with insomnia while maintaining commercial viability and clinical credibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Insomnia Pharmacological Treatment Market, by Drug Class

  • 8.1. Benzodiazepines
    • 8.1.1. Estazolam
    • 8.1.2. Temazepam
    • 8.1.3. Triazolam
  • 8.2. Melatonin Receptor Agonists
    • 8.2.1. Agomelatine
    • 8.2.2. Melatonin
    • 8.2.3. Ramelteon
  • 8.3. Non Benzodiazepine Hypnotics
    • 8.3.1. Eszopiclone
    • 8.3.2. Zaleplon
    • 8.3.3. Zolpidem
      • 8.3.3.1. Extended Release
      • 8.3.3.2. Immediate Release
  • 8.4. Orexin Receptor Antagonists
    • 8.4.1. Lemborexant
    • 8.4.2. Suvorexant
  • 8.5. Sedating Antidepressants
    • 8.5.1. Doxepin
    • 8.5.2. Trazodone

9. Insomnia Pharmacological Treatment Market, by Dosage Form

  • 9.1. Capsules
    • 9.1.1. Hard Gelatin
    • 9.1.2. Soft Gelatin
  • 9.2. Oral Suspension
  • 9.3. Tablets
    • 9.3.1. Controlled Release
    • 9.3.2. Immediate Release

10. Insomnia Pharmacological Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
    • 10.1.1. Private
    • 10.1.2. Public
  • 10.2. Online Pharmacy
    • 10.2.1. Marketplaces
    • 10.2.2. Specialty Online Pharmacies
  • 10.3. Retail Pharmacy
    • 10.3.1. Chain
    • 10.3.2. Independent

11. Insomnia Pharmacological Treatment Market, by End User

  • 11.1. Homecare Settings
    • 11.1.1. Assisted Living
    • 11.1.2. Private Homecare
  • 11.2. Hospitals
    • 11.2.1. General Hospitals
    • 11.2.2. Psychiatric Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Outpatient Clinics
    • 11.3.2. Sleep Disorder Clinics

12. Insomnia Pharmacological Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Insomnia Pharmacological Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Insomnia Pharmacological Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Insomnia Pharmacological Treatment Market

16. China Insomnia Pharmacological Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aa Pharma Inc.
  • 17.6. Amneal Pharmaceuticals LLC
  • 17.7. BlaQmax by Akay Natural Ingredients Private Limited
  • 17.8. Dr. Reddy's Laboratories
  • 17.9. Eisai Co., Ltd.
  • 17.10. Fresenius Kabi AG
  • 17.11. Gemini Pharmaceuticals
  • 17.12. Idorsia Pharmaceuticals Ltd.
  • 17.13. Ingenus Pharmaceuticals
  • 17.14. Makers Nutrition, LLC
  • 17.15. Merck & Co., Inc.
  • 17.16. Micro Labs Limited
  • 17.17. Paratek Pharmaceuticals, Inc.
  • 17.18. Pfizer Inc.
  • 17.19. Purdue Pharma L.P.
  • 17.20. Sanofi S.A.
  • 17.21. Sivem Pharmaceuticals ULC
  • 17.22. Sleepme Inc.
  • 17.23. SMP Nutra
  • 17.24. Sumitomo Pharma Co., Ltd.
  • 17.25. Takeda Pharmaceuticals Company Ltd.
  • 17.26. TriVue Pharmaceuticals, Inc.
  • 17.27. Tru Body Wellness
  • 17.28. Vanda Pharmaceuticals
  • 17.29. Vera Herbals LLC
  • 17.30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESTAZOLAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TEMAZEPAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRIAZOLAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY AGOMELATINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RAMELTEON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOXEPIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TRAZODONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PRIVATE HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PSYCHIATRIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PSYCHIATRIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY PSYCHIATRIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-20